Matching articles for "Capvaxive"
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • August 4, 2025; (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)
The Medical Letter on Drugs and Therapeutics • August 4, 2025; (Issue 1734)
...
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
The Medical Letter on Drugs and Therapeutics • October 14, 2024; (Issue 1713)
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal...
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal vaccines are currently available in the
US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and
Prevnar 13 (PCV13) are conjugate vaccines licensed
for use in persons ≥6 weeks old, and Pneumovax 23
(PPSV23) is a pneumococcal polysaccharide vaccine
licensed for use in persons ≥2 years old (see Table 1).